Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

This trial is testing two immunotherapy drugs — atezolizumab and bevacizumab — in patients with liver cancer (hepatocellular carcinoma, or HCC) that is too large or advanced for standard transplant criteria. The goal is to shrink the tumor enough to make liver transplant possible. **You may be eligible if...** - You are 18 or older with liver cancer that is outside the standard size criteria for transplant - You are otherwise healthy enough to receive a liver transplant and a procedure called TACE - You have not received prior systemic therapy for liver cancer - Your liver function is adequate (Child-Pugh score A6 or better) - You test negative for HIV and active hepatitis B **You may NOT be eligible if...** - You have received prior immunotherapy or anti-cancer systemic treatment for your liver cancer - You have moderate to severe fluid buildup in your abdomen (ascites) or a history of confusion from liver disease (hepatic encephalopathy) - You have active autoimmune disease requiring systemic treatment - You have significant heart, lung, or bleeding problems - You are pregnant or breastfeeding - You have cancer that has spread outside the liver Talk to your doctor to see if this trial is right for you.